Hydrocortisone Use During Peri-operation for Pituitary Adenomas

Surgery Clinical Trial

Official title: Withholding Hydrocortisone vs Routine Use of Hydrocortisone During Peri-operation in Pituitary Adenoma Patients With Intact Hypothalamus-Pituitary-Adrenal Axis: Randomized Controlled Trial to Assess Safety and Complications

Status Recruiting

Clinical Trial Summary

The investigators hypothesize that withholding hydrocortisone during the peri-operation in patients with pituitary adenomas whose hypothalamus pituitary adrenal axis are intact are safe.

Clinical Trial Description

Pituitary is the headquarters of the endocrine system of the body, secreting several hormones maintaining the normal function of the endocrine organs. After surgery, pituitary dysfunction is seen in a small proportion of patients, even in some patients resulting in severe consequence, i.e. adrenal insufficiency or pituitary crisis. Therefore, patients undergoing pituitary surgery have been usually given "stress dose" steroids whether their hypothalamus pituitary adrenal (HPA) axis are deficient or preserved.

Results of several retrospective studies showed that there was no significantly increase in postoperative adrenal insufficiency in no supplementation (of hydrocortisone) group than in supplementation group. Given the considerable side effects of using steroids, whether hydrocortisone administration is necessary for all patients with pituitary adenomas during peri-operation needs to be discussed.

For Chinese patients with pituitary adenomas except for those of Cushing's disease, hydrocortisone administration during the peri-operation is a routine practice. Peking Union Medical College Hospital is the China Pituitary Disease Registry Center. Here, the investigators aim to launch a single-center prospective randomized controlled trial to verify the hypothesis that withholding hydrocortisone during the peri-operation in patients with pituitary adenomas whose HPA axis are intact are safe. ;

Related Conditions & MeSH terms

• Adenoma
• Adrenal Insufficiency
• Pituitary Adenoma
• Pituitary Diseases
• Pituitary Neoplasms
• Surgery

• NCT number: NCT04621565
• Study type: Interventional
• Source: Peking Union Medical College Hospital
• Contact: Bing Xing, MD
• Phone: +861069152530
• Email: xingbingemail@aliyun.com
• Status: Recruiting
• Phase: N/A
• Start date: November 1, 2020
• Completion date: July 2022